Eli Lilly is about to release Zepbound, a new entrant in the superheated competition for blockbuster weight loss drugs.
The blockbuster weight loss drug Wegovy has a new rival. Today, the US Food and Drug Administration approved a new drug for weight management called Zepbound , made by American pharmaceutical company Eli Lilly . The weekly injectable drug is meant for adults who are overweight or obese and have at least one weight-related condition, such as high blood pressure , type 2 diabetes , or high cholesterol .
With the FDA’s approval of Zepbound, people seeking to lose weight now have another option. Like Ozempic and Wegovy, it is also started at a low dose and gradually increased. Zepbound’s approval was based on trials run by Eli Lilly that included 2,539 adults with obesity or excess weight and weight-related medical problems other than diabetes, according to the company.
FDA Weight Management Drug Zepbound Rival Wegovy Eli Lilly Overweight Obese High Blood Pressure Type 2 Diabetes High Cholesterol
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves new obesity drug from Eli Lilly named ZepboundThe decision by the Food and Drug Administration is expected to add to the demand for a new class of drugs transforming how patients battle obesity.
Read more »
Zepbound: FDA approves new version of diabetes drug Mounjaro for weight lossThe U.S. Food and Drug Administration on Wednesday approved a new version of the type 2 diabetes drug tirzepatide for use in chronic weight management, officials said.
Read more »
FDA approves a new weight loss drug, Zepbound from Eli LillyThe medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.
Read more »
New weight loss drug: FDA approves Zepbound, a version of diabetes drug Mounjaro for obesityZepbound, a new version of the popular diabetes treatment Mounjaro, can now be sold as a weight-loss drug and helped patients lose 25% of their weight.
Read more »
FDA approves Zepbound, a new obesity drug that will take on WegovyEli Lilly said the obesity medicine, which helped adults in clinical studies lose about 20% of their body weight, will be available in the U.S. by the end of the year. The list price will be $1,060.
Read more »
Zepbound: FDA approves new weight-loss drugFederal regulators say a new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug.
Read more »